Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiary Shandong Shengdi Pharmaceutical Co., Ltd. received approval from the State Drug Administration to issue a “Pharmaceutical Clinical Trial Approval Notice” for HRS-5346 tablets, agreeing to carry out phase III clinical trials of this product. Application indications: Reduce the risk of major adverse cardiovascular events in adult patients with confirmed atherosclerotic cardiovascular disease with elevated lipoprotein (a) or increased risk of first-time cardiovascular events.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.